Transcranial Direct Current Stimulation for Depression in Alzheimer's Disease Patient - Preliminary Research (ADAPT)

February 24, 2020 updated by: National Center of Neurology and Psychiatry, Japan

Ameliorating Depression in Alzheimer's Disease Patients by Transcranial Direct Current Stimulation (ADAPT) - Preliminary Research

This project will investigate the safety and efficacy of transcranial direct current stimulation (tDCS) in the treatment of depression among patients with Alzheimer's disease. The investigators aim to ameliorate depressive symptoms among patient with Alzheimer's disease, by anodal stimulation on left dorsolateral prefrontal cortex and cathodal suppression on right supraorbital area. Active stimulation will be compare to sham condition in 20 patients (10 in each groups).

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

This project will investigate the safety and efficacy of transcranial direct current stimulation (tDCS) in the treatment of depression among patients with Alzheimer's disease. tDCS causes an excitatory effect on the anode side and suppressing effect on the cathode side through sculp with very week currents (2 mA in this project). The investigators aim to ameliorate depressive symptoms among patient with Alzheimer's disease, by anodal stimulation on left dorsolateral prefrontal cortex and cathodal suppression on right supraorbital area. Active stimulation will be compare to sham condition in 20 patients (10 in each groups) from outpatient clinic in National Center of Neurology and Psychiatry, Japan.

Study Type

Interventional

Enrollment (Actual)

4

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Japan
    • Tokyo
      • Kodaira, Tokyo, Japan, 187-8551
        • National Center of Neurology and Psychiatry

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years to 90 years (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Participants who meets criteria of probable Alzheimer's disease defined by NINCDS-ADRDA research criteria.
  2. Participants who meets criteria of depression in Alzheimers defined by NIMH criteria.
  3. Participants who have been on fixed dose (including participants without any prescription) of antidepressants for at least two weeks on the screening visit.
  4. Participants who have been on fixed dose (including participants not prescribed) of antidementia drugs (donepezil, rivastigmine, galantamine, and memantine) for at least for weeks on the screening visit.
  5. Ambulatory participants with or without any aiding device
  6. Participants who have one caregiver, who must live with the patient at least ten hours a week and must report the patient's behavior.
  7. A study partner who can report how the participant is doing is needed.
  8. Eligible family member must sign and give consent on behalf of participants, whereas participants can give assent.

Exclusion Criteria: Following potential participants will be excluded

  1. In case their cognitive deficits are better explained by another disease (e.g., cerebral infarction, Parkinson disease, multiple sclerosis, normotensive hydrocephalus).
  2. In case they have history of epilepsy
  3. In case they need treatment by antipsychotics due to significant psychotic symptoms
  4. In case they have urgent risk of suicide or severe depression and any doctor require their hospitalization to psychiatric units.
  5. In case they have history of ineffectiveness with electroconvulsive therapy (ECT) or transcranial direct current stimulation (tDCS)
  6. In case ECT or tDCS is clinically contraindicated
  7. In case they are taking benzodiazepines or antiepileptic drugs on the screening visit
  8. In case they scored less than ten on Mini Mental State Exam (MMSE) or scored 3 or more on Clinical Dementia Rating (CDR)
  9. In case his/her GDS score is lower than 6 at baseline
  10. In case he/she is unable to agree video recording on evaluation interview

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Active stimulation
Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
Device: Transcranial Direct Current Stimulation
Sham Comparator: Sham stimulation
Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
Other: Sham Stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Attrition rate due to any adverse event
Time Frame: three weeks
three weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of adverse events related to tDCS procedure
Time Frame: three weeks
three weeks
Geriatric Depression Scale
Time Frame: one week, two weeks, three weeks, five weeks (followup)
a subjective scale for depressive symptoms
one week, two weeks, three weeks, five weeks (followup)
Cornell Scale for Depression in Dementia
Time Frame: two weeks, three weeks, five weeks (followup)
a objective scale for depressive symptoms
two weeks, three weeks, five weeks (followup)
Neuropsychiatric Inventory
Time Frame: three weeks, five weeks (followup)
a objective scale for neuropsychiatric symptoms
three weeks, five weeks (followup)
Zarit Burden Interview
Time Frame: three weeks, five weeks (followup)
a subjective scale for caregivers' burden
three weeks, five weeks (followup)
Clinical Global Impression of Improvement
Time Frame: one, two, three and five weeks (followup)
Clinician-rated impression of improvement
one, two, three and five weeks (followup)
Starkstein Apathy Scale
Time Frame: two, three and five weeks (followup)
a subjective scale for apathy
two, three and five weeks (followup)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Dementia Rating
Time Frame: baseline
severity of dementia
baseline
Quality of Life - Alzheimer's Disease
Time Frame: baseline
a QoL scale
baseline
ADCS-ADL
Time Frame: baseline
Alzheimer's Disease Co-operative Study - Activity of Daily Living
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Center of Neurology and Psychiatry, Japan

Investigators

  • Principal Investigator: Yuma Yokoi, MD, National Center of Neurology and Psychiatry, Japan

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2014

Primary Completion (Actual)

December 31, 2017

Study Completion (Actual)

March 15, 2018

Study Registration Dates

First Submitted

January 27, 2015

First Submitted That Met QC Criteria

January 27, 2015

First Posted (Estimate)

January 30, 2015

Study Record Updates

Last Update Posted (Actual)

February 26, 2020

Last Update Submitted That Met QC Criteria

February 24, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A2014-086

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Transcranial Direct Current Stimulation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe